Evidence map›Paper›PMID 40079152›Full record

ArticleNanomedicine (London, England)2025

Femtosecond laser-ablative aqueous synthesis of multi-drug antiviral nanoparticles.

Rebecca R Schmitt, Bruce A Davidson, Dihua He, Guang S He, Julia C Bulmahn, Suryaprakash Sambhara, Paul R Knight, Paras N Prasad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rebecca R SchmittDepartment of Chemistry and The Institute for Laser, Photonics, and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Bruce A DavidsonDepartment of Molecular Medicine, Cornell University, Ithaca, NY, USA.
Dihua HeDepartment of Molecular Medicine, Cornell University, Ithaca, NY, USA.
Guang S HeDepartment of Chemistry and The Institute for Laser, Photonics, and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Julia C BulmahnDepartment of Chemistry and The Institute for Laser, Photonics, and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Suryaprakash SambharaDepartment of Anesthesiology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Paul R KnightDepartment of Molecular Medicine, Cornell University, Ithaca, NY, USA.
Paras N PrasadDepartment of Chemistry and The Institute for Laser, Photonics, and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, USA.

Funding

Immunotherapy for acute lung injury secondary to influenzaR01HL151498 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI KNIGHT III, PAUL R · 2020 to 2023
$1.7M
NHLBI NIH HHS R01 HL151498
6 · The paper itself

Abstract

backgroundNanomedicine offers a number of innovative strategies to address major public health burdens, including complex respiratory illnesses. In this work, we introduce a multi-drug nanoparticle fabricated using femtosecond laser ablation for the treatment of influenza, SARS-CoV-2, and their co-infections.

methodsThe SARS-CoV-2 antiviral, remdesivir; the influenza antiviral, baloxavir marboxil; and the anti-inflammatory, dexamethasone, were co-crystalized and then ablated in aqueous media using a femtosecond pulsed laser and subsequently surface modified with the cationic polymer, chitosan, or poly-d-lysine. Physical and chemical properties were then characterized using multiple complimentary techniques. Finally, a clinically relevant

resultsOur final nanoparticle exhibited a positive zeta potential with a diameter of ~73 nm. Remdesivir, baloxavir marboxil, and dexamethasone were all present in the nanoparticle suspension at a 1:1:1 ratio. Notably, these particles exhibited a potent anti-influenza effect, decreasing the viral titer by ≈ 4 logs in comparison to vehicle controls.

conclusionOverall, these findings demonstrate great promise both for the use of laser ablation to generate multi-drug nanoparticles and for the anti-viral effects of our nanoformulation against respiratory illness.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentNanoparticlesAdenosine MonophosphateAlanineAnimalsChitosanCOVID-19DexamethasoneHumansInfluenza A virusLasersMicePyridonesSARS-CoV-2TriazinesAdenosine MonophosphateAlanineAntiviral AgentsChitosanDexamethasonePyridonesremdesivirTriazinesair-liquid interfaceantiviralfemtosecond laser ablationinfluenzamulti-drug nanoparticleNanomedicineSARS-CoV-2

Identifiers

PMID40079152
PMCPMC11970772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.